/publications/issue/2008/2008-10/2008-10-8713

Product News

Author:

Needle-Trap System

Schreiner MediPharm (Blauvelt, NY) recently introduced the Needle- Trap System to help prevent accidental needlestick injuries to health care providers from disposable syringes. The Needle-Trap System features an integrated safety mechanism that is a component of the self-adhesive syringe label. The simple, economical design allows the needle to be safely and easily secured after it has been used and enables health care providers to use the same injection technique and disposal process as before. The labels can be integrated easily into conventional labeling systems and are adaptable to the most common syringe types. The Needle-Trap System also can provide optional detachable documentation labels to reduce the risk of medication errors. For more information, visit www.schreiner-medipharm.com.


Granisetron Hydrochloride Injection

Parenta Pharmaceuticals (Yardley, PA), the US subsidiary of the Austrian-based Ebewe Pharma, recently launched Granisetron Hydrochloride Injection. The product is the generic equivalent of Hoffmann- LaRoche?s Kytril. Granisetron Hydrochloride Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. The product is AP-rated, bar-coded, and supplied in latex-free vials in 0.1-mg/ mL and 1-mg/mL single-dose vials and 4-mg/4-mL (1-mg/mL) multidose vials. For more information, visit www.parentarx.com, or call 800-898-9948.


Zingo (lidocaine hydrochloride monohydrate)

Anesiva Inc (South San Francisco, CA) recently launched Zingo powder intradermal injection system. Zingo is an easy-to-administer, single-use, needle-free system that delivers sterile lidocaine powder to provide topical, local analgesia to reduce the pain associated with peripheral intravenous (IV) insertions or blood draws that is approved for use in children aged 3 to 18 years. The product?s rapid onset of action allows IV line placement or venipuncture to begin 1 to 3 minutes after administration. The procedure should be performed within 10 minutes after Zingo administration. The product contains 0.5 mg of sterile lidocaine hydrochloride monohydrate. Zingo is a single-use device packaged in an individual foil/ clear pouch placed inside a bubble wrap sleeve. For more information, visit www.zingo.com, or call 866-ZINGORX (866-946-4679).


Cardene I.V. (nicardipine hydrochloride)

EKR Therapeutics Inc (Bedminster, NJ) recently received FDA approval for Cardene I.V. premixed injection?a patented, ready-to-use, single-use intravenous (IV) bag for the administration of this calcium channel blocker. The product is indicated for the shortterm treatment of hypertension when oral therapy is not feasible or not desirable. Cardene I.V. dosage must be individualized depending on the severity of hypertension and the response of the patient during dosing. Blood pressure should be monitored both during and after the infusion. The 200-mL IV bags contain 20 mg of nicardipine hydrochloride (0.1 mg/mL) in either dextrose or sodium chloride. For more information, visit www.cardeneiv.com, or call 877-435-2524.